Asset Details
Do you wish to reserve the book?
Neutralizing Antibodies against Enteroviruses in Patients with Hand, Foot and Mouth Disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Neutralizing Antibodies against Enteroviruses in Patients with Hand, Foot and Mouth Disease
Do you wish to request the book?
Neutralizing Antibodies against Enteroviruses in Patients with Hand, Foot and Mouth Disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Neutralizing Antibodies against Enteroviruses in Patients with Hand, Foot and Mouth Disease
2020
Overview
Hand, foot and mouth disease (HFMD) is an emerging infection with pandemic potential. Knowledge of neutralizing antibody responses among its pathogens is essential to inform vaccine development and epidemiologic research. We used 120 paired-plasma samples collected at enrollment and >7 days after the onset of illness from HFMD patients infected with enterovirus A71 (EV-A71), coxsackievirus A (CVA) 6, CVA10, and CVA16 to study cross neutralization. For homotypic viruses, seropositivity increased from <60% at enrollment to 97%-100% at follow-up, corresponding to seroconversion rates of 57%-93%. Seroconversion for heterotypic viruses was recorded in only 3%-23% of patients. All plasma samples from patients infected with EV-A71 subgenogroup B5 could neutralize the emerging EV-A71 subgenogroup C4. Collectively, our results support previous reports about the potential benefit of EV-A71 vaccine but highlight the necessity of multivalent vaccines to control HFMD.
Publisher
U.S. National Center for Infectious Diseases,Centers for Disease Control and Prevention
Subject
/ Antibodies, Neutralizing - immunology
/ Ataxia
/ Child
/ Diseases
/ enterovirus A71 and neutralization
/ Female
/ Fever
/ hand
/ Hand, Foot and Mouth Disease - blood
/ Hand, Foot and Mouth Disease - epidemiology
/ Hand, Foot and Mouth Disease - prevention & control
/ Hand, Foot and Mouth Disease - virology
/ Humans
/ Infant
/ Male
/ Neutralizing Antibodies against Enteroviruses in Patients with Hand, Foot and Mouth Disease
/ Patients
/ Plasma
/ Vaccines
/ viruses
